RARE logo

RARE Stock Overview

Profile

Full Name:

Ultragenyx Pharmaceutical Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

January 31, 2014

Indexes:

Not included

Website:

http://www.ultragenyx.com

Description:

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company headquartered in Novato, California, specializing in the development and implementation of new drugs for the treatment of severe rare genetic diseases. It was founded in 2010. The company focuses its efforts on developing drugs for patients with diseases that have no treatment options. Today, there are many rare genetic diseases that do not have approved therapies. The company's product portfolio includes two commercially approved products, as well as several candidates at various stages of clinical trials, which can be divided into three categories: biologics, gene therapy products, and small molecules.

Key Details

Price

$45.70

Market Cap

$4.22 B(Mid cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$560.23 M(+29.01% YoY)

Annual EPS

-$6.29(+23.76% YoY)

PE Ratio

-

Annual ROE

-214.50%

Annual Debt To Equity

0.00

Beta

0.91

Events Calendar

Earnings

Next earnings date:

May 2, 2025

Recent quarterly earnings:

Feb 13, 2025

Recent annual earnings:

Feb 13, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Oct 22, 24 Cantor Fitzgerald
Overweight
Oct 21, 24 TD Cowen
Buy
Oct 1, 24 Cantor Fitzgerald
Overweight
Sep 26, 24 RBC Capital
Outperform
Sep 20, 24 Cantor Fitzgerald
Overweight
Sep 16, 24 Cantor Fitzgerald
Overweight
Aug 5, 24 Barclays
Overweight
Aug 2, 24 Wells Fargo
Overweight
Aug 2, 24 Wedbush
Neutral
Aug 2, 24 Goldman Sachs
Buy

Screeners with RARE included

Growing Shares Outstanding
Mid cap stocks
US stocks
Stocks below SMA 200
Most recommended stocks
Stocks above SMA 50
Stocks below analysts price target
Healthcare sector
All stocks
Biotechnology industry

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$45.70
RARE price is $45.70

Price All-time High

$177.39
RARE price is currently -74.24% below its historical high of $177.39

Price Analysts Target

$86.00
RARE price is currently -46.86% lower than the consensus analysts' forecast

Price Today Change

+3.18%
RARE price is up +3.18% today

Price YTD Change

+8.63%
RARE price is up +8.63% since January 1st

Price 3-Year Change

-31.49%
RARE price is down -31.49% over the past 3 years

Market cap

Market Cap

$4.22 B
RARE market capitalization is $4.22 billion

Market Cap 3-Year Change

-8.83%
RARE market capitalization is down -8.83% over the past 3 years

Market Cap All-time High

$11.74 B
RARE market capitalization is currently -64.04% below its historical high of $11.74 billion

Market Cap Sector Rank

87.89%
RARE market capitalization is higher than 87.89% of companies in Healthcare sector

Technical

Beta

0.91
RARE beta is 0.91

200-day SMA

$47.25
RARE price is currently -3.27% below its 200-day simple moving average

14-day RSI

52.79
RARE 14-day relative strength index is 52.79

30-day Relative Volume

0.80
RARE 30-day relative volume is 0.80

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$560.23 M
RARE annual revenue is $560.23 million

Annual Revenue Analysts Estimate

$654.85 M
RARE annual revenue is currently -14.45% lower than the consensus analysts' forecast

Annual Revenue 1-Year Change

+29.01%
RARE annual revenue is up +29.01% year-on-year

Annual Revenue Sector Rank

76.25%
RARE annual revenue is higher than 76.25% of companies in Healthcare sector

Profit

Annual Gross Profit

$483.50 M
RARE annual gross profit is $483.50 million

Annual Gross Margin

86.30%
RARE annual gross profit margin is 86.30%

Annual Operating Profit

-$535.97 M
RARE annual operating income is -$535.97 million

Annual Operating Margin

-95.67%
RARE annual operating profit margin is -95.67%

Annual Net Income

-$569.18 M
RARE annual net profit is -$569.18 million

Annual Net Margin

-101.60%
RARE annual net profit margin is -101.60%

EPS

Annual EPS

-$6.29
RARE annual earnings per share is -$6.29

Annual EPS Analysts Estimate

-$5.22
RARE annual earnings per share is currently +20.54% higher than the consensus analysts' forecast

Annual EPS 1-Year Change

+23.76%
RARE annual earnings per share is up +23.76% year-on-year

Annual EPS Sector Rank

19.46%
RARE annual earnings per share is higher than 19.46% of companies in Healthcare sector

ROA & ROE

Annual ROA

-38.02%
RARE annual return on assets is -38.02%

Annual ROE

-214.50%
RARE annual return on equity is -214.50%

EBIT & EBITDA

Annual EBIT

-$504.55 M
RARE annual earnings before interest & taxes is -$504.55 million

Annual EBITDA

-$504.55 M
RARE annual EBITDA is -$504.55 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
RARE price to earnings ratio value is unknown

PE Ratio Sector Rank

-
RARE price to earnings ratio is unknown

PB Ratio

PB Ratio

16.53
RARE price to book ratio is 16.53

PB Ratio Sector Rank

95.23%
RARE price to book ratio is higher than 95.23% of companies in Healthcare sector

PS Ratio

PS Ratio

7.53
RARE price to sales ratio is 7.53

PS Ratio Sector Rank

70.57%
RARE price to sales ratio is higher than 70.57% of companies in Healthcare sector

Enterprise value

Enterprise Value

-
RARE enterprise value value is unknown

Enterprise Value Sector Rank

-
RARE enterprise value is unknown

EV/EBITDA

EV/EBITDA

-
RARE EV/EBITDA value is unknown

EV/EBITDA Sector Rank

-
RARE EV/EBITDA is unknown

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

-
RARE annual current ratio value is unknown

Annual Quick Ratio

-
RARE annual quick ratio value is unknown

Leverage

Annual Debt To Equity

0.00
RARE annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

-8.00
RARE annual interest coverage ratio is -8.00

Risk & Stability

Piotroski F-Score

-
RARE piotroski f-score value is unknown

Altman Z-Score

-
RARE altman z-score value is unknown

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$1.50 B
RARE annual total assets is $1.50 billion

Annual Non Current Assets

-
RARE annual long term assets value is unknown

Annual Current Assets

$745.03 M
RARE annual total current assets is $745.03 million

Annual Cash & Cash Equivalents

-
RARE annual cash & cash equivalents value is unknown

Equity

Annual Book Value

$255.30 M
RARE annual book value is $255.30 million

Annual Working Capital

-
RARE annual working capital value is unknown

Liabilities

Annual Total Liabilities

$1.25 B
RARE annual total liabilities is $1.25 billion

Annual Total Long Term Liabilities

-
RARE annual total long term liabilities value is unknown

Annual Current Liabilities

-
RARE annual total current liabilities value is unknown

Annual Accounts Payable

-
RARE annual accounts payable value is unknown

Debt

Annual Total Debt

$0.00
RARE annual total debt is $0.00

Annual Total Debt 1-Year Change

-100%
RARE annual total debt is down -100% year-on-year

Annual Long Term Debt

-
RARE annual long term debt value is unknown

Annual Short Term Debt

-
RARE annual short term debt value is unknown

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$1.10 B
RARE annual total expenses is $1.10 billion

Annual Operating Expenses

$1.02 B
RARE annual total operating expenses is $1.02 billion

Annual Cost Of Goods Sold

$76.73 M
RARE annual cost of goods sold is $76.73 million

Annual SGA

$321.61 M
RARE annual SGA is $321.61 million

Annual D&A

-
RARE annual depreciation & amortization value is unknown

Annual Interest Expense

$63.04 M
RARE annual interest expense is $63.04 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-
RARE annual cash flow from operations value is unknown

Annual CFO 1-Year Change

-
RARE annual cash flow from operations 1-year change is unknown

Annual CFI

-
RARE annual cash flow from investing activities value is unknown

Annual CFI 1-Year Change

-
RARE annual cash flow from investing activities 1-year change is unknown

Annual CFF

-
RARE annual cash flow from financing activities value is unknown

Annual CFF 1-Year Change

-
RARE annual cash flow from financing activities 1-year change is unknown

Free CashFlow

Annual FCF

-
RARE annual free cash flow value is unknown

Annual FCF 1-Year Change

-
RARE annual free cash flow 1-year change is unknown

CAPEX

Annual CAPEX

-
RARE annual capital expenditures value is unknown

Annual CAPEX 1-Year Change

-
RARE annual capital expenditures 1-year change is unknown

Institutional Ownership

Similar stocks

ICUI logo
ICU Medical (ICUI)
OSCR logo
Oscar Health (OSCR)
PBH logo
Prestige Consumer Healthcare (PBH)
BHVN logo
Biohaven Pharmaceutical Holding (BHVN)
OGN logo
Organon & Co (OGN)
PTCT logo
PTC Therapeutics (PTCT)
SHC logo
Sotera Health (SHC)
RNA logo
Avidity Biosciences (RNA)
ACHC logo
Acadia Healthcare (ACHC)

FAQ

  • What is the ticker symbol for Ultragenyx Pharmaceutical?
  • Does Ultragenyx Pharmaceutical pay dividends?
  • What sector is Ultragenyx Pharmaceutical in?
  • What industry is Ultragenyx Pharmaceutical in?
  • What country is Ultragenyx Pharmaceutical based in?
  • When did Ultragenyx Pharmaceutical go public?
  • Is Ultragenyx Pharmaceutical in the S&P 500?
  • Is Ultragenyx Pharmaceutical in the NASDAQ 100?
  • Is Ultragenyx Pharmaceutical in the Dow Jones?
  • When was Ultragenyx Pharmaceutical's last earnings report?
  • When does Ultragenyx Pharmaceutical report earnings?
  • Should I buy Ultragenyx Pharmaceutical stock now?

What is the ticker symbol for Ultragenyx Pharmaceutical?

The ticker symbol for Ultragenyx Pharmaceutical is NASDAQ:RARE

Does Ultragenyx Pharmaceutical pay dividends?

No, Ultragenyx Pharmaceutical does not pay dividends

What sector is Ultragenyx Pharmaceutical in?

Ultragenyx Pharmaceutical is in the Healthcare sector

What industry is Ultragenyx Pharmaceutical in?

Ultragenyx Pharmaceutical is in the Biotechnology industry

What country is Ultragenyx Pharmaceutical based in?

Ultragenyx Pharmaceutical is headquartered in United States

When did Ultragenyx Pharmaceutical go public?

Ultragenyx Pharmaceutical's initial public offering (IPO) was on January 31, 2014

Is Ultragenyx Pharmaceutical in the S&P 500?

No, Ultragenyx Pharmaceutical is not included in the S&P 500 index

Is Ultragenyx Pharmaceutical in the NASDAQ 100?

No, Ultragenyx Pharmaceutical is not included in the NASDAQ 100 index

Is Ultragenyx Pharmaceutical in the Dow Jones?

No, Ultragenyx Pharmaceutical is not included in the Dow Jones index

When was Ultragenyx Pharmaceutical's last earnings report?

Ultragenyx Pharmaceutical's most recent earnings report was on Feb 13, 2025

When does Ultragenyx Pharmaceutical report earnings?

The next expected earnings date for Ultragenyx Pharmaceutical is May 2, 2025

Should I buy Ultragenyx Pharmaceutical stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions